

Small RNA Mcr11 regulates genes involved in the central metabolism of *Mycobacterium tuberculosis* and requires 3' sequence along with the transcription factor AbmR for stable expression

Roxie C. Girardin¹ and Kathleen A. McDonough^{1,2*}

¹Department of Biomedical Sciences, School of Public Health, University at Albany, PO Box 22002, Albany, NY 12201-2002

²Wadsworth Center, New York State Department of Health

*To whom correspondence should be sent:

Kathleen A. McDonough, PhD

Wadsworth Center

120 New Scotland Avenue

PO Box 22002, Albany, NY 12201-2002

Phone: (518) 486-4253

Fax: (518) 402-4773

Email: kathleen.mcdonough@health.ny.gov

Running Title: Expression and function of mycobacterial small RNA Mcr11

Keywords: sRNA targets, RNA termination, RNA stability, gene regulation, lipoylation

Abstract

Mycobacterium tuberculosis (Mtb), the etiologic agent of tuberculosis, must adapt to host-associated environments during infection by modulating gene expression. Small regulatory RNAs (sRNAs) are key regulators of bacterial gene expression, but their roles in Mtb are not well understood. Here, we address the expression and function of the Mtb sRNA Mcr11, which is associated with slow bacterial growth and latent infections in mice. We found, by using biochemical and genetic approaches, that the AbmR transcription factor and an extended region of native sequence 3' to the *mcr11* gene enhance production of mature Mcr11. Additionally, we found that expression of Mcr11 was unstable in the saprophyte *Mycobacterium smegmatis*, which lacks an *mcr11* orthologue. Bioinformatic analyses used to predict regulatory targets of Mcr11 identified 9-11 nucleotide regions immediately upstream of Rv3282 and *lipB* with potential for direct base-pairing with Mcr11. *mcr11*-dependent regulation of Rv3282, *lipB*, Rv2216 and *pknA* was demonstrated using qRT-PCR in wild type versus *mcr11*-deleted Mtb and found to be responsive to the presence of fatty acids. These studies establish that Mcr11 has roles in regulating growth and central metabolism in Mtb that warrant further investigation. In addition, our finding that multiple factors are required for production of stable, mature Mcr11 emphasizes the need to study mechanisms of sRNA expression and stability in TB complex mycobacteria to understand their roles in TB pathogenesis.

Author Summary

Bacterial pathogens must continuously modulate their gene expression in response to changing conditions to successfully infect and survive within their hosts. Transcription factors are well known regulators of gene expression, but there is growing recognition that small RNAs (sRNAs) also have critically important roles in bacterial gene regulation. Many sRNAs have been identified in *M. tuberculosis* (Mtb), but little is known about their expression, regulatory targets or roles in Mtb biology. In this study, we found that the Mtb sRNA Mcr11, which is expressed at high levels in slowly replicating Mtb and during mouse infection, regulates expression of several target genes involved in central metabolism. Importantly, we also discovered that *mcr11* has unexpected requirements for stable expression in mycobacteria. In particular, we identified RNA sequence elements immediately downstream of *mcr11* that enhance transcription termination and production of mature Mcr11 RNA in TB-complex mycobacteria. Meanwhile, ectopic expression of Mcr11 was unstable in a non-pathogenic strain of mycobacteria, suggesting that factors specific to pathogenic mycobacteria are required for the stable production of Mcr11. These studies identify sRNA stability as a new frontier for understanding gene expression in Mtb.

Introduction

Tuberculosis (TB) remains a major threat to global public health, with at least 10 million new, incident cases and 1.3 million deaths due to TB in 2017 (1). The basic biology of *Mycobacterium tuberculosis* (Mtb), the etiological agent of TB, is poorly understood despite its importance to the development of new therapeutic interventions. Mtb can adopt a specialized physiological state within host tissues, which renders the bacteria phenotypically drug resistant and viable despite extended periods of slow or non-replicating persistence (NRP) (2). NRP and phenotypic drug resistance pose particular challenges for intervention, making it critical to understand the regulatory processes that enable Mtb to adapt to host conditions.

Bacterial and host factors that contribute to NRP and slow growth are still being defined (3). Host-associated environmental cues that result in metabolic remodeling and a shift away from active growth toward a state of persistence include hypoxia, nitrosative stress, redox stress, nutrient starvation, as well as adaptation to cholesterol and fatty acid metabolism (4-9). Isocitrate lyases (ICLs) are used by bacteria to maintain growth on fatty acids through the glyoxylate shunt, and are critical for Mtb's ability to survive on fatty acids and within the host (10-12). Surprisingly, ICLs are also required for growth on carbohydrate carbon sources (13), and gluconeogenesis is required for Mtb virulence (14-16). Additionally, lipoylated enzymes involved in the citric acid cycle, such as lipoamide dehydrogenase (Lpd) and dihydrolipoamide acyltransferase (DlaT), are necessary for Mtb survival in the host and viability

during NRP (17-19). However, factors that regulate these processes are not well understood.

Gene expression studies have provided critical insights into the regulation and function of proteins like transcription factors that modulate gene expression as *Mtb* adapts to the host environment during infection (20, 21). The additional role of sRNAs in gene regulation is recognized in other bacteria (22), and several sRNAs whose expression is responsive to stress and/ or growth phase have been identified in mycobacteria (23-28). (23-26, 29-31). It also has been observed that over expression of some sRNAs leads to slow or delayed growth in mycobacteria (23, 32). However, the importance of these differentially expressed sRNAs to the adaptation and survival of *Mtb* during periods of stress has not been fully addressed.

The intergenic sRNA *Mcr11* (*ncRv11264Ac*) is one of the best-studied mycobacterial sRNAs (24, 26, 29, 33). Expression of *Mcr11* is regulated in response to advanced growth phase and levels of the universal second messenger 3',5'-cyclic adenosine monophosphate (cAMP) (24, 26, 29). Additionally, *Mcr11* is abundantly expressed by *Mtb* in the lungs of chronically infected mice (26) as well as in hypoxic and non-replicating *Mtb* (32). Transcriptional regulators of *mcr11* expression include the product of the adjacent, divergently expressed gene *abmR* (*Rv1265*) (33), and the cAMP binding transcription factor (TF) CRP_{MT} (29). The structure and function of *Mcr11* in TB-complex mycobacteria is unknown, prompting us to further characterize this sRNA.

Here, we report that cis-acting, extended, native sequence 3' to Mcr11 enhances production of Mcr11 in mycobacteria. Optimal Mcr11 termination efficiency needed the transcription factor AbmR and was regulated by growth phase in Mtb and *Mycobacterium bovis* BCG, but not in the fast-growing saprophyte *Mycobacterium smegmatis*. We found that *mcr11* regulates expression of *lipB* and *Rv3282*, which contribute to central metabolic pathways associated with NRP and slow growth in Mtb. In addition, Mcr11 affected growth of both Mtb and BCG in hypoxic conditions without fatty acids. This study identifies TB complex-specific cis and trans factors required for stable Mcr11 expression while providing the first report of *mcr11*-dependent regulation of gene targets in Mtb.

Results

Modeling secondary structure of Mcr11

Previous studies established two 5' ends of Mcr11 at chromosomal positions 1413224 and 1413227 in *Mycobacterium tuberculosis* H37Rv (24, 29), but the 3' end of Mcr11 is poorly defined. Preliminary efforts to express Mcr11 based on size estimates from prior Northern blot experiments were not successful, despite the well-mapped 5' end of the sRNA. Secondary structural features of sRNAs greatly contribute to their function, and RNA folding is most strongly influenced by the nucleotide sequence of the RNA (34, 35). We reasoned that defining the precise boundaries of Mcr11 could help in identifying its function.

We mapped the 3' end of Mcr11 to chromosomal positions 1413107 and 1413108 in *Mycobacterium tuberculosis* (Mtb) using 3' rapid amplification of cNDA ends (RACE) and Sanger sequencing (Figure 1A). These 3' ends are 120 and 119 nucleotides (nt) downstream from the most abundant previously mapped 5' end at position 1413227 (24). Our mapped 3' ends vary 3-4 nucleotides from the 3' end at chromosomal position 1413111 inferred by deep sequencing (36), and are 13-14 nt shorter than the 3' end estimated by cloning (24) (Figure 1A). These results indicate that Mcr11 is a transcript between 117 and 121 nt long, which is consistent with its observed size by Northern blot (24, 26, 29).

The mapped 3' ends of Mcr11 at chromosomal positions 1413107/1413108 varied by 3-13 nt from previous estimates of the 3' end of Mcr11, so we considered the possibility that this variance could be functionally significant.

Transcriptional termination occurs in prokaryotes by two described mechanisms: Rho-dependent termination and intrinsic, Rho-independent termination (37-39). Rho-dependent termination requires the association of the ATP-hydrolyzing molecular motor Rho with the nascent RNA, which is typically cytosine-enriched, guanosine-depleted and unstructured at the 3' end (40). Intrinsic, Rho-independent termination is governed by the formation of a structured termination hairpin that is usually followed a poly-U tail, and is highly dependent upon the sequence of the nascent RNA. Several mycobacterial sRNAs have multiple reported 3' ends, suggestive of Rho-dependent termination and/or post-transcriptional processing (23, 30, 31). However, relatively little is known about transcriptional termination in Mtb, particularly at sRNAs (41-45).

We modeled the secondary structure of Mcr11 with varying lengths of extended, native 3' RNA sequence by using RNA Structure (46) to reveal potential functional features. Mcr11 was predicted to be highly structured, with few single-stranded (ss) regions available for potential base-pairing with regulatory target RNA sequences (Figure 1B). Use of either mapped 5' end of *mcr11* produced the same Mcr11 secondary structure, as these 5' nucleotides are predicted to be unpaired (Figure 1B). Modeled structures of extended native sequence 3' to our mapped ends of *mcr11* revealed additional highly structured motifs with similarity to predicted Rho-independent terminators (RITs) downstream of *mcr11* in mycobacteria (43, 44). However, none included the long, characteristic poly-U tail found in RITs of other bacteria (38). A 10 nt region containing a sub-optimal poly-U tract was identified by scanning sequence

downstream of the mapped 3' end of Mcr11 in the constructs that contained 3' sequence elements (TSEs) 2-4 (Figure 1A). Modeling the secondary structure of this sequence revealed a stem loop structure with a 7nt trail containing 4 discontinuous Us (Figure 1C).

Measurement of TSE function in Msm

We tested the impact of different *mcr11* TSEs on the transcriptional termination of Mcr11 using promoter:*mcr11*:TSE:*GFPv* reporter constructs (Figure 2A-B). We reasoned that transcriptional termination levels could be inferred by using *GFPv* fluorescence as a relative measure of transcriptional read-through beyond the *mcr11* gene (Figure 2A). The relative percentage of termination for each TSE was calculated by dividing the observed fluorescence of each *Pmcr11*:TSE:*GFPv* strain by the observed fluorescence of an *mcr11* promoter-only:*GFPv* construct (*Pmcr11*:*GFPv*), subtracting the product from 1, and multiplying the result by 100. Promoterless *GFPv* served as a negative assay control, and an *mcr11*-independent promoter:*GFPv* fusion construct served as a positive assay control. A positive intrinsic termination control was generated by fusing *mcr11* and a small amount of native 3' trailing sequence to a synthetic RIT (tt_{sbi}B) that has been shown to function at ~98% efficiency with Mtb RNAP *in vitro* (Figure 1B) (42).

Our initial termination experiments measuring TSE efficiency were performed in Msm, because it lacks an *mcr11* orthologue and thus has no basal Mcr11 expression. The inclusion of any TSE sequence at the 3' end of *mcr11*

resulted in decreased transcriptional read-through of the *mcr11*:GFPv fusion reporter, as compared to the relative levels of GFPv fluorescence for *Pmcr11* alone (Figure 2B). This result suggested that all TSEs supported transcriptional termination to varying degrees. Longer TSEs had greater termination efficiency, but the positive *tt_{sbi}B* intrinsic termination control exhibited the strongest mean termination efficiency at 88% (Figure 2C). Paraformaldehyde-fixed duplicates of each sample were subjected to flow cytometry analysis to determine if the mean GFPv fluorescence observed in our plate-based assay was reflective of the fluorescence observed in individual cells, or if there were populations of cells with varying levels of fluorescence. A single, homogenous population of fluorescent cells was observed for each reporter, demonstrating that mean fluorescence measured in the plate reader assay was representative of the fluorescence in individual cells (Supplemental Figure 2). From these data, we concluded that mean fluorescence reflected relative termination efficiency for each TSE reporter.

Northern blot analysis was performed to further evaluate the expression of *Mcr11* in *Msm*. We noted that the size of *Mcr11* did not vary in *Msm* despite the presence of TSEs with various lengths, suggesting that TSEs are rapidly processed off of the mature sRNA if they are transcribed (Figure 2D). *Mcr11* was also present at very low levels in *Msm* when compared to a BCG control for which 1/3 the amount of total RNA present in the *Msm* samples was loaded in the gel (Figure 2D). These results are consistent with the possibility of reduced *Mcr11* expression and/or stability in *Msm* compared to BCG.

TB complex- specific factors are required for stable Mcr11 expression

mcr11 expression varies across growth phases in TB complex mycobacteria (24, 33), so we examined the effect of growth phase on *mcr11* expression in Msm. Fluorescence from the GFPv transcriptional reporters was measured at mid-log and late stationary phase. Surprisingly, we observed that *Pmcr11* activity was not increased by advancing growth phase when expressed in Msm (Figure 2E), suggesting that a positive regulatory factor was absent.

Previously, we showed that the divergently expressed DNA-binding protein AbmR is a growth phase-responsive activator of *mcr11* expression (33). Although the Msm orthologue (*MSMEG_5010*) of *abmR* displays both high amino acid sequence identity (68.75%) and amino acid similarity (83.51%) to AbmR (33), we hypothesized that *abmR* has functionality that the Msm orthologue lacks. Thus, we added a copy of the Mtb *abmR* locus upstream of the *Pmcr11::GFPv* fusion sequences and tested the activity of *Pmcr11* in response to growth phase in Msm. The addition of *abmR* significantly increased *Pmcr11* activity in Msm, and rendered *Pmcr11* activity responsive to growth phase (Figure 2E), as previously observed in BCG and Mtb (33). However, inclusion of *abmR* did not significantly increase the amount of stable Mcr11 detected by Northern blot in Msm (Figure 2D), indicating that Mcr11 is unstable when transcribed in Msm. Together, these results show that Mtb *abmR* regulates *mcr11* expression at the transcriptional level, but is not sufficient for stable Mcr11 expression in a non-native environment.

Further studies in TB-complex mycobacteria showed that the termination efficiencies of *mcr11* TSEs in mid-log phase BCG were similar to those observed in Msm (Figure 3), but only BCG showed enhanced *mcr11* TSE termination efficiencies in late stationary phase. This growth-phase dependent increase in termination efficiency in BCG was strongest for TSE1, which improved from approximately 40% to 70% (Figure 3C). Overall termination efficiencies of *mcr11* TSEs were also greater in virulent Mtb (H37Rv) than in BCG or Msm (Figure 3D-F). Deletion of *abmR* caused a small but significant decrease in *mcr11* termination efficiencies from all constructs, with the TSE1 short hairpin being the most strongly affected (Supplemental Figure 3). Together, these data indicate that multiple trans-acting factors specific to the genetic background of TB-complex mycobacteria facilitate the transcriptional termination and production of stable Mcr11.

Longer TSEs enhance expression of Mcr11 in TB-complex mycobacteria

We expected that increased termination efficiencies would correlate with higher levels of mature Mcr11 in TB complex mycobacteria. Thus, we used Northern blot analyses to measure the production of stable Mcr11 from various *mcr11* TSE constructs in $\Delta mcr11$ strains of BCG and Mtb during late stationary phase (Figure 4). Robust levels of Mcr11 were produced from constructs containing native *mcr11* TSEs. As was observed in experiments with Msm, Mcr11 size remained constant despite its expression with TSEs of different

lengths in BCG or Mtb (Figure 4). This size restriction is consistent with precise termination or an RNA processing event that produces discrete 3' ends.

We considered the possibility that expression of *mcr11* in the context of an mRNA with a translated, stable transgene such as *GFPv* could contribute to the stability of Mcr11. Production of Mcr11 from *mcr11:TSE1* constructs was compared to Mcr11 levels from a similar construct in which *GFPv* is not immediately downstream of TSE1 (Figure 5A). Mcr11 levels were not affected by the *GFPv* location (Figure 5B), indicating that *GFPv* did not contribute to the production or processing of stable Mcr11 in these experiments. This conclusion is also consistent with the low levels of Mcr11 observed in Msm despite the presence of the *GFPv* transgene (Figure 2D).

As advancing growth phase significantly improved the termination efficiencies of TSEs in BCG (Figure 3C), we tested the effects of growth phase on the expression of *mcr11*. Mcr11 levels were observed by Northern blot (Figure 5C) and measured by qRT-PCR (Figure 5D) in BCG Δ *mcr11* strains carrying ectopic copies of either *mcr11:TSE1* or *mcr11:TSE3*. Both constructs showed growth-phase dependent increases in expression of stable Mcr11 (Figure 5C and 5D). Stress conditions can modulate the efficiency of RITs (47) and induce the appearance of multiple, different size products of a single sRNA in Mtb (23, 27). However, neither BCG nor Mtb displayed significant stress-induced changes in the termination efficiencies of *mcr11* TSEs (Supplemental Table 3) when subjected to nitrosative stress (DETA-NO), ATP depletion (BDQ), DNA damage

(OFX), or transcriptional stress (RIF). These data demonstrate the significant role that differences in native 3' sequence have on stable Mcr11 expression.

Identification of Mcr11 regulatory targets

Having identified the sequence features required for robust ectopic production of Mcr11 in complemented $\Delta mcr11$ strains, we considered *mcr11* function. A bioinformatic search of potential regulatory targets of Mcr11 using TargetRNA (48) and TargetRNA2 (49) identified *abmR* as the top-scoring hit (Figure 6A) (Supplemental Table 4). We measured the relative abundance of AbmR protein by Western blot analysis, and found that it was decreased in BGC $\Delta mcr11$ and Mtb $\Delta mcr11$ (Figure 6B,C). However, recent reports indicate that the *abmR* mRNA is a leaderless transcript that lacks a 5' UTR (50), so the region of direct base-pair complementarity with the Mcr11 sRNA and the 5' end of *abmR* predicted by TargetRNA is not likely to be present in the *abmR* mRNA (50). We also previously showed that the *mcr11* gene overlaps a substantial portion of the DNA sequences identified as the upstream enhancer and promoter regions for *abmR* transcription (Figure 6A) (33, 51).

We addressed the possibility that *mcr11* deletion has cis rather than trans effects on *abmR* expression due to disruption of *abmR* regulatory sequences. Promoter:*lacZ* reporter studies were used to compare *PabmR* activity in the presence and absence of flanking *mcr11* sequences in Wt BCG and Mtb backgrounds that express Wt levels of Mcr11. Transcriptional activity from the minimal *abmR* promoter lacking adjacent sequence in the *mcr11* gene was much

lower than that from the extended *abmR* promoter that includes contiguous *mcr11* gene sequences (Figure 6D). These assays were conducted in the Wt backgrounds of BCG and Mtb with comparable levels of native *mcr11* expression in all matched strains, indicating that sequence overlapping the *mcr11* gene was required in cis for full *abmR* promoter activity. We conclude that the reduced expression of *abmR* in $\Delta mcr11$ strains is likely due to the loss of sequence-based *abmR* regulatory elements within the *mcr11* gene rather than a trans-acting regulatory effect of Mcr11 on *abmR* expression.

TargetRNA also predicted multiple putative targets of Mcr11 regulation, including two genes within operons involved in central metabolic processes and cell division: *lipB* (encodes lipoate protein ligase B, needed for lipoate biosynthesis) (Figure 7A) and *Rv3282* (encodes a conserved hypothetical protein with homology to Maf septum-site inhibition protein) (Figure 7B). The intergenic spacing between putative target gene *fadA3* (*Rv1074c*), which encodes a beta-ketoacyl coenzyme A thiolase, and the preceding gene (*Rv1075c*) is identical to that of the intergenic spacing between *Rv2216* and *lipB*. However, *fadA3* is likely to be transcribed independently of *Rv1075c* (50). *lipB* and *Rv3282* were selected for follow-up because they are essential, associated with growth and central metabolism of Mtb, and contain predicted Mcr11 base-pairing sequences that are within known mRNA transcript boundaries. Each of these target transcripts has the potential to interact with Mcr11 through a 9-11 nt continuous base pairing region, followed by a shorter stretch of gapped or imperfect base pairing (Figure 7A and 7B). A region from nt 39-55 of Mcr11 was predicted to interact with these

mRNA targets and others (Figure 7C and 7D, Supplemental Table 4), which includes a region of Mcr11 predicted to be in an unpaired loop in multiple modeled secondary structures of Mcr11 (Supplemental Figure 4).

Fatty acids affect Mcr11-dependent regulation of target genes in Mtb

The *lipB* operon includes *dlaT*, which encodes DlaT, the E2 component of pyruvate dehydrogenase (PDH) and the peroxynitrite reductase/peroxidase (PNR/P) complex in Mtb. The function of DlaT is modulated by lipoylation, which is dependent upon lipoate biosynthesis by LipB (18, 52). BkdC (also called PdhC or Rv2495c) is a component of the branched chain keto-acid dehydrogenase (BCKADH) complex in Mtb that also requires lipoylation for activity. Disruption of components in any of these complexes can cause growth defects in Mtb, some of which are dependent upon the nutrient mixture present in the growth media (18, 19). The genes upstream of Rv3282 are *accD5* and *accE5*, which are needed for a long chain acetyl-CoA carboxylase enzymatic complex that generates substrates for fatty acid and mycolic acid biosynthesis (53, 54).

We used qRT-PCR to measure expression of genes within the operons containing predicted Mcr11-regulatory targets *lipB* and Rv3282 in Wt versus $\Delta mcr11$ strains. Gene expression was queried in stationary phase BCG and Mtb grown in media with (+OA) or without (-OA) fatty acids to assess the impact of Mcr11 regulatory function in these conditions. Tween-80® is a hydrolysable detergent that can release a substantial amount of fatty acids (primarily oleic acid), and so was replaced with the non-hydrolysable detergent Tyloxapol in media lacking fatty acids. The *mcr11* complements included TSE4 with or without

an intact copy of *abmR*. Levels of *phoP*, a response regulator expected to be independent of *mcr11* and *abmR*, and *pknA*, a serine-threonine protein kinase required for growth, were also measured.

Expression of *Rv3282*, *Rv2216*, *lipB* and *pknA* was significantly de-repressed in *Mtb*Δ*mcr11* compared to Wt *Mtb* in the absence, but not the presence, of fatty acids. In contrast, levels of *lipB* and *pknA* expression decreased in the *mcr11* *Mtb* mutant when fatty acids were present. Complementation of *mcr11* fully (*Rv3282*, *pknA*) or partially (*Rv2216*, *lipB*) restored expression to Wt levels (Figure 8A). The expression of *accD5* (*Rv3280*) was significantly de-repressed and *accE5* (*Rv3281*) trended toward de-repression in *Mtb*Δ*mcr11*, and complementation partially restored Wt levels of expression of both genes (Supplemental Figure 5A). Expression of *dlaT* and *phoP* were not altered in *Mtb* (Figure 8A). From these data, we concluded that Mcr11-mediated regulation expression of *Rv3282*, *Rv2216*, *lipB* and *pknA* expression in stationary phase *Mtb* is affected by the levels of fatty acids in the media. In contrast, no Mcr11-dependent regulation of the putative target genes was observed in BCG other than a trend of higher *Rv3282* expression in BCGΔ*mcr11* relative to Wt BCG (Figure 8C and 8D). These data demonstrate that *mcr11*-dependent regulation of specific target genes is responsive to the fatty acid content of the culture media, and suggest that Mcr11 has a role in regulating the central metabolism of *Mtb*.

Expression levels of mRNA do not always match expression levels of the cognate protein if a gene is subjected to multiple layers of regulation. We tested if

the protein levels of PknA or lipoylated DiaT were altered in *MtbΔmcr11* by Western blot. No significant differences in the abundance of PknA or lipoylated DiaT were observed between *MtbΔmcr11* and Wt *Mtb* (Supplemental Figure 5B). It is possible that de-repression of *lipB* does not affect DiaT lipoylation if lipoate is limiting or if wild-type levels are already saturating for lipoylation of DiaT.

Mcr11 is required for optimal growth of BCG and Mtb without fatty acids

Optimal growth of *Mtb* on carbohydrate-based carbon sources requires appropriate *dlaT* expression (18, 19) and *lipB*, *accD5*, and *accE5* are essential for the growth of *Mtb* (55, 56). Mutations in *Rv3282* delay *Mtb* growth, even in nutrient rich media (55). Based on our observed regulation of these genes by *Mcr11*, we hypothesized that *Δmcr11* deleted strains would exhibit a growth defect when forced to utilize carbohydrate carbon sources for growth in media lacking a source of fatty acids.

No growth differences were observed between Wt and *Δmcr11* mutant *Mtb* or BCG in media containing fatty acids. However, BCG*Δmcr11* was severely growth-lagged and *MtbΔmcr11* was moderately growth delayed compared to Wt bacteria when grown in media lacking fatty acids (Figure 8E-H). Complementation with *mcr11* partially complemented growth in BCG and fully restored growth to Wt levels in *Mtb* (Figure 8G and 8E). From these data, we conclude that *mcr11* has a role in the central metabolism and growth of BCG and *Mtb*.

Discussion

This work identifies several genes associated with central metabolism in Mtb as regulatory targets of the sRNA Mcr11. We also demonstrated that transcriptional termination and stable production of the sRNA Mcr11 is enhanced by extended native sequence 3' to *mcr11* along with the product of the divergently transcribed adjacent gene, *abmR*. The regulation of central metabolism in Mtb is consistent with *mcr11* expression profiles in response to growth phase and *in vivo* infection (26, 33). However, the additional requirements for TB complex specific factors for stable Mcr11 expression were unexpected, and this may have broader implications for understanding sRNA expression in Mtb.

Characterization of the factors required for efficient termination and stable expression of Mcr11 was a prerequisite for the complementation studies that confirmed Mcr11 regulatory targets. Protein coding mRNAs often can tolerate variable amounts of 5' and 3' flanking sequence because the signals for protein expression are provided immediately upstream and within the open reading frame (ORF). In contrast, expression of functional sRNAs may be more dependent on RNA chaperones and/or processing factors, as well as cis-acting sequence elements at their transcriptional boundaries that may be difficult to define (25, 47, 57-59). Defining the role of these cis-acting sequences for *mcr11* and possibly other sRNAs in Mtb is an important topic for future studies.

Mechanism of *mcr11* transcriptional termination

Sequences at the 3' end of sRNAs can be critical for stability, function and interaction with RNA chaperones, although such chaperones have yet to be identified in mycobacteria (25, 59-64). The role of extended native 3' sequences for expression of mycobacterial sRNAs warrants further investigation to determine whether *mcr11* is exceptional or representative of a larger group of sRNAs with regards to expression and stability requirements.

A recent study of Rho function in Mtb (41) found that depletion of Rho did not impact transcriptional boundaries at predicted RITs (43, 44), demonstrating a clear separation in the populations of transcripts terminated by RITs and Rho-dependent mechanisms. While we found that TSEs promote expression of *Mcr11*, their underlying mechanism remains unclear and our data do not precisely fit either the current RIT or Rho-dependent termination models (Table 1). We propose a model in which *mcr11* processing occurs immediately following, or concurrent with, Rho-dependent termination.

Table 1: Comparison of transcription termination types

Features	Rho-Dependent	Intrinsic	Mcr11
Predicted hairpin in 3' sequence		✓	✓
Unstructured, C-rich 3' sequence	✓		
Poly U-tract in 3' sequence		✓	
Extrinsic factor(s) required	✓		✓
Transcription factor may impact functionality	✓	✓	✓

Rho-independent termination is considered “intrinsic” because extrinsic accessory factors are not required for function (38). Our results clearly indicate that production of stable Mcr11 requires factors other than the TSEs (Figs. 2D and 4). The species-specific effects we observed for *mcr11* termination measured by the GFPv reporter assays suggest that bacterial-specific factors affect the efficiency of *mcr11* termination itself, although the effects on Mcr11 stability are more striking (Figs. 2-4).

Rho utilization (rut) sites are degenerate and difficult to predict using bioinformatics approaches, but transcripts terminated by Rho tend to have C-enriched, G-depleted 3' ends that are thought to be unstructured (40). It is not clear if there is a rut site within *mcr11*, as the sequences downstream of the 3' end of Mcr11 are predicted to be highly structured and are rich in both G and C (Fig. 1). A run of 6Cs (nucleotides 93-98) occurs within Mcr11, but this region may be highly structured (Fig. 1). In contrast, Mcr11 TSEs 2-4, which contributed strongly to the termination of Mcr11, all possess C-rich loops in their predicted secondary structures that could be rut sites (Fig. 1). Rho-significant regions (RSRs) reported in the Botella et al study (41) include an RSR that begins 6 nt downstream of the mapped 3' end of Mcr11, that is characterized as a region of general antisense transcription. The presence of this RSR is consistent with the possibility that *mcr11* expression is Rho-terminated. Mcr10 (*ncRv1157a*) is also proximal to an RSR (41). Future work is needed to establish the importance of Rho-dependent termination for mycobacterial sRNAs.

In *Escherichia coli*, multiple trans-acting factors are known to modulate termination and anti-termination of Rho-terminated sRNAs (65). AbmR, an ATP-responsive DNA-binding transcription factor that activates *mcr11* expression (33), was found here to also positively regulate termination efficiency of *mcr11*. Despite the high similarity between *abmR* and its Msm orthologue (33), *MSM_5010* failed to strongly activate *mcr11* expression and Mcr11 transcripts were unstable in Msm, even when *abmR* was provided in trans. It is possible that AbmR interacts directly with RNAP or Rho to affect termination, or recruits an as yet undefined trans-acting factor that modulates Mcr11 termination in Mtb. It will also be important to determine which specific sequence or structural elements in the TSEs of *mcr11* contribute to transcriptional termination versus processing, and the extent to which similar TSEs are associated with other sRNAs in mycobacteria.

The discrete 3' end of mature Mcr11 observed by Northern blot is consistent with a processed or precisely terminated RNA, as transcription through TSEs would otherwise result in RNAs significantly longer products. Processing of the 3' ends of mycobacterial sRNAs has been proposed (31), and a recent report identified a hypoxia-regulated mycobacterial sRNA that is extensively processed at its 3' end (25). The observed size variants of specific sRNA species in response to host-associated stress conditions (23) provide further evidence for processing of sRNAs in mycobacteria.

Processing mechanisms for tRNAs and sRNAs have been defined, particularly for transcripts terminated by RITs in *E. coli* (57, 66-70). Recent work

has demonstrated that Rho terminated transcripts have processed 3' ends immediately downstream of a stable stem-loop (71). The processing of these discrete ends is dependent on the redundant action of the 3' → 5' exonucleases PNPase and RNase II, and it was speculated that the stem-loop promotes stabilization of the processed transcript (71). While few RNA processing enzymes of mycobacteria have been well characterized, the Mtb genome encodes many known RNases with varying sequence specificities (72-77). We speculate that unidentified TB-complex RNA chaperones and/or modifying enzymes contribute to Mcr11 stability, and that their absence in Msm results in Mcr11 degradation.

Regulation of predicted targets of Mcr11

Oleic acid is the main fatty acid present in rich mycobacterial media formulations, provided either directly as oleic acid or in the hydrolyzable, nonionic detergent Tween-80®. The presence of Tween-80® can alter acid resistance (78), enhances the growth of mycobacteria when combined with glucose or glycerol (79, 80), and increases the uptake of glucose by BCG (79, 80). While we did not observe sensitivity to acid in BCGΔ*mcr11* or BCGΔ*abmR* (data not shown), *mcr11* was required for growth on media lacking added fatty acids. Nutrient rich media is often used in batch culture experimentation with Mtb, and the potential confounding effect of multiple nutrient sources on characterizing the essentiality and function of gene products has recently gained appreciation (36, 81). Future studies characterizing nutrient uptake in Mtb and BCG strains of

511 *Δmcr11* or *ΔabmR* will further our understanding of the nutrient related growth
512 defects of these strains.

513 Two metabolic enzymes critical for Mtb pathogenesis are known to be
514 lipoylated in Mtb, including dihydrolipoamide acyltransferase (DlaT) and BkdC, a
515 component of the Lpd-dependent branched chain keto-acid dehydrogenase
516 (BCKADH) ([18](#)). Lipoylation in Mtb is presumed to depend solely on lipoate
517 synthesis by the enzymes LipA and the Mcr11 target LipB, as scavenging and
518 import pathways are apparently lacking ([52](#)). *Rv3282* has homology to Maf, a
519 septum inhibition protein conserved across all domains of life ([82](#), [83](#)). It is in a
520 putative operon with *accD5* and *accE5*, which encode a probable propionyl-
521 coenzyme A carboxylase involved in the detoxification of propionate using the
522 methylmalonyl pathway to produce methyl-branched virulence lipids ([84](#)). Despite
523 *mcr11*-dependent regulation of *Rv3282* in the absence of fatty acids, *MtbΔmcr11*
524 did not have a filamentous cell morphology (data not shown) and the function of
525 *Rv3282* in Mtb has not been defined. The regulation of Mcr11's targets was
526 responsive to the fatty acid content of the growth media, and it will be important
527 to determine if the observed growth defects of *MtbΔmcr11* are due to the
528 dysregulation of *lipB* and *Rv3282*, or if there are additional targets of Mcr11
529 regulation that account for this phenotype (Figure 9). Additionally, the role of
530 Mcr11 in supporting the growth and persistence of Mtb in response to nutrient
531 availability and growth arrest should be explored.

532 Mcr11-dependent regulation of *lipB* and *Rv3282* expression is expected to
533 occur through base-pairing with the mRNA, although future work is needed to

establish the mechanism (Figure 7). The sRNA RyhB is known to differentially regulate expression of individual genes within the *iscRSUA* operon, resulting in down-regulation of the *icsSUA* genes while maintaining expression of *iscR* (85). This mechanism requires an intra-cistronic base-pairing dependent translational blockade of *iscS*, followed by recruitment of RNaseE and selective degradation of the 3' end of the mRNA. The position of both putative Mcr11 base-pairing sites within target gene operons raises multiple possibilities for *mcr11*-mediated regulation of co-transcribed genes that will be an intriguing topic for future study. We noted that the *mcr11* target interaction site within the intergenic region of *Rv2216* and *lipB* had identical spacing to that of *Rv1075c* and *fadA3*, although the significance of this architecture is unknown.

This study shows that the transcriptional termination and stability of the sRNA Mcr11 is enhanced by extended, native 3' sequence elements (TSEs) in TB complex mycobacteria. The role of AbmR in *mcr11* expression was extended from that of a transcriptional activator to include enhancement of *mcr11* transcriptional termination. Our observation that bacterial-species specific factors govern sRNA stability in mycobacteria may also extend to other sRNAs. Combined use of bioinformatic and molecular tools established fatty acid responsive, *mcr11*-dependent gene regulation in Mtb and provides a versatile strategy for the continued search of sRNA function in pathogenic mycobacteria. Future work defining the precise roles of the sRNA Mcr11 in regulating the growth and metabolism of Mtb will greatly advance our understanding of this important pathogen.

Materials and Methods

Bacterial Strains and Growth Conditions

Mycobacterium tuberculosis H37Rv (Mtb) (ATCC 25618) and *Mycobacterium bovis* BCG (BCG) (Pasteur strain, Trudeau Institute) were grown on 7H10 agar (Difco) supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC) (Becton Dickson and Company) and 0.01% cycloheximide or in Middlebrook 7H9 liquid medium (Difco) supplemented with 10% (vol/vol) OADC, 0.2% (vol/vol) glycerol, and 0.05% (vol/vol) Tween-80 (Sigma-Aldrich) in physiologically relevant shaking, hypoxic conditions (1.3% O₂, 5% CO₂) (86) for promoter::reporter fusion assays and Northern blot analysis. *Mycobacterium smegmatis* mc²155 (Msm) (ATCC 700048) was grown in Middlebrook 7H9 liquid medium (Difco) supplemented with 10% (vol/vol) OADC, 0.2% (vol/vol) glycerol, and 0.05% (vol/vol) Tween-80 (Sigma-Aldrich), shaking in ambient air for promoter::reporter fusion assays and Northern blot analysis. All experiments were started from low-passage frozen stocks. For cloning experiments, *Escherichia coli* strains were grown on Luria-Bertani (Difco) agar plates or in liquid broth. Growth media and plates were supplemented with 50 µg/mL hygromycin, 25 µg/mL kanamycin (Sigma-Aldrich) for selection of clones. All bacterial cultures were incubated at 37°C.

Mutant Strain Construction

Knockout strains of *mcr11* in Mtb and BCG genetic backgrounds were generated using homologous recombination (87) to replace nucleotides 1-100 with a hygromycin resistance cassette. Disruption of *mcr11* was confirmed with

polymerase chain reaction (PCR) (Supplemental Figure 1B. and 1C.) and Northern blot analysis (Supplemental Figure 1D. and 1E.). Several complementation constructs were created to restore Mcr11 expression. Sequence from the corrected *abmR* (Rv1265) start site (51) to the end of the Rv1264 ORF was amplified by PCR and cloned downstream of the *efTu* (Rv0685) promoter in the multi-copy plasmid pMBC280, creating pMBC1211. PCR was used to amplify varying lengths of sequence from the end of the Rv1264 ORF through the end of the *abmR* ORF, and they were cloned it into pMBC409, which contains a kanamycin resistance marker, to create pMBC2040, pMBC2041, and pMBC2042 (Supplemental Figure 1A.). Complementation plasmids were sequenced to verify that the desired sequences had been correctly incorporated and then used to transform Mtb and BCG by electroporation. A complete list of plasmids used in this study are provided in Supplemental Table 1 and primers are listed in Supplemental Table 2.

Mapping the 3' End of Mcr11

RNA was harvested from late-log phase Mtb and the 3' end of Mcr11 was mapped using the miScript Reverse Transcription Kit (Qiagen) (88) and a gene-specific primer. The reaction product was cloned into pCRII-TOPO vector (Life Technologies) and ten positive clones were subjected to Sanger sequencing. The sequences were mapped back to the chromosome of Mtb.

Bioinformatic Modeling of Mcr11

Secondary structure modeling of Mcr11 and putative native intrinsic terminators was performed using RNAstructure using default parameters (46).

Color-coded base-pair drawings of predicted RNA secondary structures were created with Visualization Applet for RNA (VARNA) (89) and simplified line drawings were made in Inkscape (inkscape.org). A synthetic terminator (tt_{sbi}B) (90) was modeled onto Mcr11 as well. Secondary structure modeling of Mcr11 was performed using RNAstructure (46). Using the previously published 5' and 3' boundaries of Mcr11, minimum free energy (MFE) and centroid structures for Mcr11 derived from CentroidFold (using the CONTRAfold inference engine), Mfold, NUPACK, RNAfold, and RNAstructure algorithms were created (46, 91-94). Base-pair drawings of predicted RNA secondary structures were either directly exported from the software used, or created with Visualization Applet for RNA (VARNA) (89) and simplified line drawings were made in Inkscape (inkscape.org).

Regulatory targets of Mcr11 in Mtb were predicted using TargetRNA (48) and TargetRNA2 algorithms (49), set to default parameters (Table3). Where possible, the position of predicted regions of base-pairing between Mcr11 and a putative regulatory target were evaluated against known 5' ends of mRNAs in Mtb (50) (Table 3).

Promoter::Reporter Fusion Assays

Promoter::lacZ fusions were created to compare the relative transcriptional activities from DNA sequences spanning the intergenic space between *Rv1264* and *abmR*, and *mcr11* and *abmR* (Supplemental Figure 2). The promoters of *gyrB* (*Rv0005*) and *efTu* (*Rv0685*) were used as positive controls, and a promoterless construct was used as a negative control. The relevant constructs

were transformed into wild-type (Wt) strains of BCG and Mtb and assayed for β -galactosidase activity in late log phase cultures grown in ambient, shaking conditions by adding 5-acetylaminofluoresceindi- β -D-galactopyranoside (C₂FDG; Molecular Probes) and measuring fluorescence in a Cytofluor 4000 fluorometer (PerSeptive Biosystems) as described previously (95).

Constructs including the *mcr11* promoter, Mcr11 sequence, and various potential intrinsic terminator sequences were fused to the reporter green fluorescent protein Venus (GFPv) on an integrating plasmid as previously described (33). A GFPv fluorescence assay was used to measure promoter activity and read-through of the putative intrinsic terminators of Mcr11 in Msm, BCG, and Mtb.

At mid-log phase and late stationary phase, aliquots of recombinant strains were collected and gently sonicated (setting 4, 4 pulses of 5" on time interspersed by 5' off time) using a Virsonic 475 Ultrasonic Cell Disrupter with a cup horn attachment (VirTis Company) before duplicate samples were diluted 1:1 in fresh media. The level of fluorescence in arbitrary units from the GFPv reporter strain was detected using the CytoFluor Multi-Well Plate Reader Series 4000 (PerSeptive Biosystems) at 485 nm excitation and 530 nm emission. The optical density (OD) at 620 nm was read using a Tecan Sunrise® microplate reader and fluorescence levels were normalized to 10⁶ bacteria. A promotorless (-) construct was used as a negative control and the promoters *Ptuf* and *Pgyr* served as positive controls. The % termination was calculated by dividing the observed GFPv fluorescence in arbitrary units of each indicated terminator construct by the

amount of GFPv fluorescence in arbitrary units measured from the *mcr11* promoter.

Late stationary phase reporter strains of BCG and Mtb were diluted with fresh media to an OD_{620 nm} of 1.25 in a 12 well plate, and then subjected to a variety of cellular stressors for a 24 hour period in shaking, hypoxic conditions (1.3% O₂, 5% CO₂). Cells were treated with 250 µM diethyltriamine-NO (DETA-NO) (Sigma-Aldrich), 1 µg per ml ofloxacin (OFX), 0.28 µg per ml rifampacin (RIF), 53 µg per ml bedaquiline (BDQ), or 0.1% dimethyl sulfoxide (DMSO) vehicle control. GFPv fluorescence in arbitrary units per 10⁶ bacteria (by measured OD at 620 nm) was monitored as described above, and percent termination was calculated relative to *Pmcr11* controls.

Fluorescence-Activated Cell Sorting Analysis

Fluorescence-activated cell sorting analysis was performed on Msm samples that had been fixed with 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) at pH 7.0 for 30 minutes at room temperature. Fixation was quenched pH-adjusted glycine, and cells were washed three times with PBS. Cells were diluted approximately 1:500 in DPBS and subjected to FACS analysis with a FACS Calibur (Becton Dickson) as previously described (96). Data was collected for 20,000 events per sample and analyzed in CellQuest software (Becton Dickenson).

RNA Isolation

Total RNA was harvested from Msm, BCG and Mtb after cultures were treated 0.5 M final GTC solution (5.0 M guanadinium isothiocyanate, 25 mM

sodium citrate, 0.5% sarkosyl, and 0.1 M 2- β -mercaptoethanol) and pelleted at 4°C. Pelleted cells were resuspended in TRIzol Reagent (Invitrogen) and cells were disrupted with 0.1 mm zirconia-silica beads (BioSpec Products) and three 70-second high-speed pulse treatments in a bead-beater (BioSpec Products). RNA was recovered from lysates with Direct-zol Mini Prep columns (Zymo) per the manufacturer's protocol. RNA was eluted from the column with nuclease free-water, treated with DNaseI (Qiagen) for 20 minutes at room temperature, and isopropanol precipitated. One μ g of total RNA was screened for DNA contamination by PCR using primers KM1309 and KM1310 internal to the sigA ORF. The quality of each RNA sample was assessed by running 1.0 μ g of DNA-free RNA on a 0.1% (weight/vol) SDS-agarose gel and visualizing intact 23S, 16S, and 5S ribosomal RNA bands after staining with ethidium bromide (Sigma-Aldrich).

Northern Blots

High quality DNA-free total RNA isolated from Msm, BCG, and Mtb was used for Northern blot analysis of Mcr11 expression. 3-10 μ g RNA was separated on a 10% 8 M urea PAGE run at a constant current of 20 mA for 1-1.5 h. The gel was electroblotted onto a Hybond N (Millipore) nylon membrane using a wet transfer system (Bio-Rad Laboratories) as previously described (Girardin, in prep). Blots were UV cross-linked and baked at 80°C for 2 h prior to pre-hybridization at 42°C for 1 h in Ravid-Hyb Buffer (GE Healthcare Life Sciences). Hybridization with α -³²P-ATP end-labeled DNA oligo probes was performed at

42°C for 2-16 h. Blots were washed per the manufacturer's protocol and exposed to phosphor-screens for visualization.

Generation of Mycobacterial Cell Lysates and Western Blotting

Strains of BCG and Mtb were grown in the desired condition, and pelleted and washed twice in ice-cold Dulbecco's phosphate buffered saline, calcium and magnesium free (DPBS-CMF), with 0.2% protease inhibitor (Sigma-Aldrich). Cell pellets were resuspended in 1/25 volume lysis buffer (0.3% SDS, 200 mM DTT, 28 mM Tris-HCl, 22 mM Tris-Base, and 1% protease inhibitor cocktail) and disrupted by two rounds of high-powered sonication at 4°C with Virsonic 475 Ultrasonic Cell Disrupter with a cup horn attachment (VirTis Company) interspersed with 10 freeze-thaw cycles as previously described (33). Lysate was cleared by centrifugation and the cleared lysate was heat-killed at 95°C before quantification with a NanoDrop 2000 (Thermo Scientific).

A total of 30 µg protein of each sample was separated by 12-15% Tris-glycine SDS-PAGE, and gels were immunoblotted on Immobilon-P membranes (Millipore) for 1h at 1 mA/cm² using a wet transfer system (Bio-Rad Laboratories). Blots were blocked and probed with 1° antibody in 5% milk (vol/vol) in 50 mM Tris-buffered saline with 0.05% (vol/vol) Tween-20 (Fisher Scientific). Monoclonal antibodies against *Mycobacterium tuberculosis* GlcB (Gene Rv1837c), Clone α-GlcB (produced *in vitro* NR-13799) was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH. Polyclonal mouse AbmR anti-serum was previously generated in-house (33). Polyclonal rabbit anti-lipoic acid antibody (EMD

Millipore catalogue # 437695-100ul) was obtained from Fisher Scientific. Primary antibodies were detected with peroxidase conjugated goat secondary antibody and enhanced chemiluminescence (ECL) western blotting detection reagent (Thermo Scientific).

Growth Curve Analysis

The growth of BCG and Mtb in hypoxic (1.3% O₂, 5% CO₂), shaking conditions were monitored by measuring the optical density at 620 nm (OD₆₂₀) of gently sonicated aliquots of cells with a Tecan Sunrise® microplate reader. Cultures were grown in vented T25 tissue culture flasks (Corning), and time points were in single or multi-day intervals. Growth comparisons between Middlebrook 7H9 + 0.2% glycerol, 10% OADC, and 0.05% Tween-80 (+OA) or in Middlebrook 7H9 + 0.2% glycerol, 10% ADC, and 0.05% Tyloxapol (-OA) were made.

Acknowledgements

We are very grateful to Dr. Guangchun Bai and Damen Schaak for generating the *mcr11* knockout strains of BCG and Mtb used in this study. We also thank Dr. Joseph Wade for helpful discussions, and gratefully acknowledge the Wadsworth Center Applied Genomics Technologies Core for DNA sequencing and the Wadsworth Center Media and Tissue Culture Core for media preparation.

References

1. WHO. Global Tuberculosis Report 2018. Geneva: World Health Organization, 2018. 2018.
2. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. *Tuberculosis*. 2004;84(1-2):29-44.
3. Bergkessel M, Basta DW, Newman DK. The physiology of growth arrest: uniting molecular and environmental microbiology. *Nat Rev Microbiol*. 2016;14(9):549-62.
4. Garton NJ, Waddell SJ, Sherratt AL, Lee SM, Smith RJ, Senner C, et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. *PLoS medicine*. 2008;5(4):e75.
5. Honaker RW, Dhiman RK, Narayanasamy P, Crick DC, Voskuil MI. DosS responds to a reduced electron transport system to induce the Mycobacterium tuberculosis DosR regulon. *J Bacteriol*. 2010;192(24):6447-55.
6. Iona E, Pardini M, Mustazzolu A, Piccaro G, Nisini R, Fattorini L, et al. Mycobacterium tuberculosis gene expression at different stages of hypoxia-induced dormancy and upon resuscitation. *Journal of microbiology (Seoul, Korea)*. 2016;54(8):565-72.
7. Schubert OT, Ludwig C, Kogadeeva M, Zimmermann M, Rosenberger G, Gengenbacher M, et al. Absolute Proteome Composition and Dynamics during Dormancy and Resuscitation of Mycobacterium tuberculosis. *Cell Host Microbe*. 2015;18(1):96-108.
8. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. *Molecular Microbiology*. 2002;43(3):717-31.
9. Shi L, Sohaskey CD, Kana BD, Dawes S, North RJ, Mizrahi V, et al. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. *Proc Natl Acad Sci U S A*. 2005;102(43):15629-34.
10. Eoh H, Rhee KY. Methylcitrate cycle defines the bactericidal essentiality of isocitrate lyase for survival of Mycobacterium tuberculosis on fatty acids. *Proc Natl Acad Sci U S A*. 2014;111(13):4976-81.
11. McKinney JD, Honer zu Bentrop K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. *Nature*. 2000;406(6797):735-8.
12. Munoz-Elias EJ, McKinney JD. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. *Nature medicine*. 2005;11(6):638-44.
13. Beste DJ, Bonde B, Hawkins N, Ward JL, Beale MH, Noack S, et al. (1)(3)C metabolic flux analysis identifies an unusual route for pyruvate dissimilation in mycobacteria which requires isocitrate lyase and carbon dioxide fixation. *PLoS Pathog*. 2011;7(7):e1002091.
14. Ganapathy U, Marrero J, Calhoun S, Eoh H, de Carvalho LP, Rhee K, et al. Two enzymes with redundant fructose bisphosphatase activity sustain

785 gluconeogenesis and virulence in *Mycobacterium tuberculosis*. *Nat Commun*.
786 2015;6:7912.

787 15. Gutka HJ, Wang Y, Franzblau SG, Movahedzadeh F. *glpx* Gene in
788 *Mycobacterium tuberculosis* Is Required for In Vitro Gluconeogenic Growth and
789 In Vivo Survival. *PLoS One*. 2015;10(9):e0138436.

790 16. Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S. Gluconeogenic
791 carbon flow of tricarboxylic acid cycle intermediates is critical for *Mycobacterium*
792 *tuberculosis* to establish and maintain infection. *Proc Natl Acad Sci U S A*.
793 2010;107(21):9819-24.

794 17. Bryk R, Gold B, Venugopal A, Singh J, Samy R, Pupek K, et al. Selective
795 killing of nonreplicating mycobacteria. *Cell Host Microbe*. 2008;3(3):137-45.

796 18. Venugopal A, Bryk R, Shi S, Rhee K, Rath P, Schnappinger D, et al.
797 Virulence of *Mycobacterium tuberculosis* depends on lipoamide dehydrogenase,
798 a member of three multienzyme complexes. *Cell Host Microbe*. 2011;9(1):21-31.

799 19. Shi S, Ehrt S. Dihydrolipoamide acyltransferase is critical for
800 *Mycobacterium tuberculosis* pathogenesis. *Infect Immun*. 2006;74(1):56-63.

801 20. Mvubu NE, Pillay B, Gamielien J, Bishai W, Pillay M. Canonical
802 pathways, networks and transcriptional factor regulation by clinical strains of
803 *Mycobacterium tuberculosis* in pulmonary alveolar epithelial cells. *Tuberculosis*
804 (Edinb). 2016;97:73-85.

805 21. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, et al.
806 Transcriptional Adaptation of *Mycobacterium tuberculosis* within Macrophages:
807 Insights into the Phagosomal Environment. *J Exp Med*. 2003;198(5):693-704.

808 22. Waters LS, Storz G. Regulatory RNAs in bacteria. *Cell*. 2009;136(4):615-
809 28.

810 23. Arnvig KB, Young DB. Identification of small RNAs in *Mycobacterium*
811 *tuberculosis*. *Mol Microbiol*. 2009;73(3):397-408.

812 24. DiChiara JM, Contreras-Martinez LM, Livny J, Smith D, McDonough KA,
813 Belfort M. Multiple small RNAs identified in *Mycobacterium bovis* BCG are also
814 expressed in *Mycobacterium tuberculosis* and *Mycobacterium smegmatis*.
815 *Nucleic Acids Res*. 2010;38(12):4067-78.

816 25. Moores A, Riesco AB, Schwenk S, Arnvig KB. Expression, maturation and
817 turnover of DrrS, an unusually stable, DosR regulated small RNA in
818 *Mycobacterium tuberculosis*. *PLoS One*. 2017;12(3):e0174079.

819 26. Pelly S, Bishai WR, Lamichhane G. A screen for non-coding RNA in
820 *Mycobacterium tuberculosis* reveals a cAMP-responsive RNA that is expressed
821 during infection. *Gene*. 2012;500(1):85-92.

822 27. Namouchi A, Gomez-Munoz M, Frye SA, Moen LV, Rognes T, Tonjum T,
823 et al. The *Mycobacterium tuberculosis* transcriptional landscape under genotoxic
824 stress. *BMC Genomics*. 2016;17(1):791.

825 28. Gerrick ER, Barbier T, Chase MR, Xu R, Francois J, Lin VH, et al. Small
826 RNA profiling in *Mycobacterium tuberculosis* identifies Mrsl as necessary for an
827 anticipatory iron sparing response. *Proc Natl Acad Sci U S A*.
828 2018;115(25):6464-9.

829 29. Arnvig KB, Comas I, Thomson NR, Houghton J, Boshoff HI, Croucher NJ,
830 et al. Sequence-based analysis uncovers an abundance of non-coding RNA in

831 the total transcriptome of *Mycobacterium tuberculosis*. PLoS Pathog.
832 2011;7(11):e1002342.

833 30. Miotto P, Forti F, Ambrosi A, Pellin D, Veiga DF, Balazsi G, et al.
834 Genome-wide discovery of small RNAs in *Mycobacterium tuberculosis*. PLoS
835 One. 2012;7(12):e51950.

836 31. Tsai CH, Baranowski C, Livny J, McDonough KA, Wade JT, Contreras
837 LM. Identification of novel sRNAs in mycobacterial species. PLoS One.
838 2013;8(11):e79411.

839 32. Ignatov DV, Salina EG, Fursov MV, Skvortsov TA, Azhikina TL,
840 Kaprelyants AS. Dormant non-culturable *Mycobacterium tuberculosis* retains
841 stable low-abundant mRNA. BMC Genomics. 2015;16:954.

842 33. Girardin RC, Bai G, He J, Sui H, McDonough KA. AbmR (Rv1265) is a
843 Novel Transcription Factor of *Mycobacterium tuberculosis* That Regulates Host
844 Cell Association and Expression of the Non-coding Small RNA Mcr11. Mol
845 Microbiol. 2018.

846 34. Dubey AK, Baker CS, Romeo T, Babitzke P. RNA sequence and
847 secondary structure participate in high-affinity CsrA-RNA interaction. RNA.
848 2005;11(10):1579-87.

849 35. Hnilicova J, Jirat Matejckova J, Sikova M, Pospisil J, Halada P, Panek J,
850 et al. Ms1, a novel sRNA interacting with the RNA polymerase core in
851 mycobacteria. Nucleic Acids Res. 2014;42(18):11763-76.

852 36. DeJesus MA, Gerrick ER, Xu W, Park SW, Long JE, Boutte CC, et al.
853 Comprehensive Essentiality Analysis of the *Mycobacterium tuberculosis* Genome
854 via Saturating Transposon Mutagenesis. MBio. 2017;8(1).

855 37. Mooney RA, Landick R. Building a better stop sign: understanding the
856 signals that terminate transcription. Nat Methods. 2013;10(7):618-9.

857 38. Ray-Soni A, Bellecourt MJ, Landick R. Mechanisms of Bacterial
858 Transcription Termination: All Good Things Must End. Annu Rev Biochem.
859 2016;85:319-47.

860 39. Santangelo TJ, Artsimovitch I. Termination and antitermination: RNA
861 polymerase runs a stop sign. Nat Rev Microbiol. 2011;9(5):319-29.

862 40. Peters JM, Mooney RA, Kuan PF, Rowland JL, Keles S, Landick R. Rho
863 directs widespread termination of intragenic and stable RNA transcription. Proc
864 Natl Acad Sci U S A. 2009;106(36):15406-11.

865 41. Botella L, Vaubourgeix J, Livny J, Schnappinger D. Depleting
866 *Mycobacterium tuberculosis* of the transcription termination factor Rho causes
867 pervasive transcription and rapid death. Nat Commun. 2017;8:14731.

868 42. Czyz A, Mooney RA, Iaconi A, Landick R. Mycobacterial RNA polymerase
869 requires a U-tract at intrinsic terminators and is aided by NusG at suboptimal
870 terminators. MBio. 2014;5(2):e00931.

871 43. Gardner PP, Barquist L, Bateman A, Nawrocki EP, Weinberg Z. RNIE:
872 genome-wide prediction of bacterial intrinsic terminators. Nucleic Acids Res.
873 2011;39(14):5845-52.

874 44. Mitra A, Angamuthu K, Nagaraja V. Genome-wide analysis of the intrinsic
875 terminators of transcription across the genus *Mycobacterium*. Tuberculosis
876 (Edinb). 2008;88(6):566-75.

877 45. Arnvig KB, Pennell S, Gopal B, Colston MJ. A high-affinity interaction
878 between NusA and the *rrn* nut site in *Mycobacterium tuberculosis*. *Proc Natl*
879 *Acad Sci U S A*. 2004;101(22):8325-30.

880 46. Mathews DH. RNA Secondary Structure Analysis Using RNAstructure.
881 *Current Protocols in Bioinformatics*: John Wiley & Sons, Inc.; 2002.

882 47. Morita T, Ueda M, Kubo K, Aiba H. Insights into transcription termination
883 of Hfq-binding sRNAs of *Escherichia coli* and characterization of readthrough
884 products. *RNA*. 2015;21(8):1490-501.

885 48. Tjaden B. TargetRNA: a tool for predicting targets of small RNA action in
886 bacteria. *Nucleic Acids Res*. 2008;36(Web Server issue):W109-13.

887 49. Kery MB, Feldman M, Livny J, Tjaden B. TargetRNA2: identifying targets
888 of small regulatory RNAs in bacteria. *Nucleic Acids Res*. 2014;42(Web Server
889 issue):W124-9.

890 50. Cortes T, Schubert OT, Rose G, Arnvig KB, Comas I, Aebersold R, et al.
891 Genome-wide mapping of transcriptional start sites defines an extensive
892 leaderless transcriptome in *Mycobacterium tuberculosis*. *Cell Rep*.
893 2013;5(4):1121-31.

894 51. Gazdik MA, Bai G, Wu Y, McDonough KA. Rv1675c (*cmr*) regulates
895 intramacrophage and cyclic AMP-induced gene expression in *Mycobacterium*
896 *tuberculosis*-complex mycobacteria. *Mol Microbiol*. 2009;71(2):434-48.

897 52. Spalding MD, Prigge ST. Lipoic acid metabolism in microbial pathogens.
898 *Microbiol Mol Biol Rev*. 2010;74(2):200-28.

899 53. Bazet Lyonnet B, Diacovich L, Cabruja M, Bardou F, Quemard A, Gago G,
900 et al. Pleiotropic effect of AccD5 and AccE5 depletion in acyl-coenzyme A
901 carboxylase activity and in lipid biosynthesis in mycobacteria. *PLoS One*.
902 2014;9(6):e99853.

903 54. Bazet Lyonnet B, Diacovich L, Gago G, Spina L, Bardou F, Lemassu A, et
904 al. Functional reconstitution of the *Mycobacterium tuberculosis* long-chain acyl-
905 CoA carboxylase from multiple acyl-CoA subunits. *FEBS J*. 2017;284(7):1110-
906 25.

907 55. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial
908 growth defined by high density mutagenesis. *Molecular Microbiology*.
909 2003;48(1):77-84.

910 56. Sassetti CM, Rubin EJ. Genetic requirements for mycobacterial survival
911 during infection. *Proc Natl Acad Sci U S A*. 2003;100(22):12989-94.

912 57. Chae H, Han K, Kim KS, Park H, Lee J, Lee Y. Rho-dependent
913 termination of *ssrS* (6S RNA) transcription in *Escherichia coli*: implication for 3'
914 processing of 6S RNA and expression of downstream *ygfA* (putative 5-formyl-
915 tetrahydrofolate cyclo-ligase). *J Biol Chem*. 2011;286(1):114-22.

916 58. Kriner MA, Sevostyanova A, Groisman EA. Learning from the Leaders:
917 Gene Regulation by the Transcription Termination Factor Rho. *Trends in*
918 *biochemical sciences*. 2016;41(8):690-9.

919 59. Patrick R, Shiflett KJT-M, Ryszard Michalczyk, Louis A. "Pete" Silks, and
920 Goutam Gupta. Structural Studies on the Hairpins at the 3' Untranslated Region
921 of an Anthrax Toxin Gene. *Biochemistry* 2003;42(20):6078-89.

60. Ishikawa H, Otaka H, Maki K, Morita T, Aiba H. The functional Hfq-binding module of bacterial sRNAs consists of a double or single hairpin preceded by a U-rich sequence and followed by a 3' poly(U) tail. *RNA*. 2012;18(5):1062-74.
61. Johnson CM, Chen Y, Lee H, Ke A, Weaver KE, Dunny GM. Identification of a conserved branched RNA structure that functions as a factor-independent terminator. *Proc Natl Acad Sci U S A*. 2014;111(9):3573-8.
62. Regnier P, Hajnsdorf E. The interplay of Hfq, poly(A) polymerase I and exoribonucleases at the 3' ends of RNAs resulting from Rho-independent termination: A tentative model. *RNA Biol*. 2013;10(4):602-9.
63. Sauer E, Weichenrieder O. Structural basis for RNA 3'-end recognition by Hfq. *Proc Natl Acad Sci U S A*. 2011;108(32):13065-70.
64. Olejniczak M, Storz G. ProQ/FinO-domain proteins: another ubiquitous family of RNA matchmakers? *Mol Microbiol*. 2017;104(6):905-15.
65. Rabhi M, Espeli O, Schwartz A, Cayrol B, Rahmouni AR, Arluison V, et al. The Sm-like RNA chaperone Hfq mediates transcription antitermination at Rho-dependent terminators. *EMBO J*. 2011;30(14):2805-16.
66. Agrawal A, Mohanty BK, Kushner SR. Processing of the seven valine tRNAs in *Escherichia coli* involves novel features of RNase P. *Nucleic Acids Res*. 2014;42(17):11166-79.
67. Chao Y, Li L, Girodat D, Forstner KU, Said N, Corcoran C, et al. In Vivo Cleavage Map Illuminates the Central Role of RNase E in Coding and Non-coding RNA Pathways. *Mol Cell*. 2017;65(1):39-51.
68. Gopel Y, Khan MA, Gorke B. Domain swapping between homologous bacterial small RNAs dissects processing and Hfq binding determinants and uncovers an aptamer for conditional RNase E cleavage. *Nucleic Acids Res*. 2016;44(2):824-37.
69. Mohanty BK, Kushner SR. Processing of the *Escherichia coli* leuX tRNA transcript, encoding tRNA(Leu5), requires either the 3'→5' exoribonuclease polynucleotide phosphorylase or RNase P to remove the Rho-independent transcription terminator. *Nucleic Acids Res*. 2010;38(2):597-607.
70. Mohanty BK, Petree JR, Kushner SR. Endonucleolytic cleavages by RNase E generate the mature 3' termini of the three proline tRNAs in *Escherichia coli*. *Nucleic Acids Res*. 2016;44(13):6350-62.
71. Dar D, Sorek R. High-resolution RNA 3'-ends mapping of bacterial Rho-dependent transcripts. *Nucleic Acids Res*. 2018;46(13):6797-805.
72. Abendroth J, Ollodart A, Andrews ES, Myler PJ, Staker BL, Edwards TE, et al. *Mycobacterium tuberculosis* Rv2179c protein establishes a new exoribonuclease family with broad phylogenetic distribution. *J Biol Chem*. 2014;289(4):2139-47.
73. Taverniti V, Forti F, Ghisotti D, Putzer H. *Mycobacterium smegmatis* RNase J is a 5'-3' exo-/endoribonuclease and both RNase J and RNase E are involved in ribosomal RNA maturation. *Mol Microbiol*. 2011;82(5):1260-76.
74. Uson ML, Ordonez H, Shuman S. *Mycobacterium smegmatis* Hely Is an RNA-Activated ATPase/dATPase and 3'-to-5' Helicase That Unwinds 3'-Tailed RNA Duplexes and RNA:DNA Hybrids. *J Bacteriol*. 2015;197(19):3057-65.

967 75. Zeller ME, Csanadi A, Miczak A, Rose T, Bizebard T, Kaberdin VR.
968 Quaternary structure and biochemical properties of mycobacterial RNase E/G.
969 The Biochemical journal. 2007;403(1):207-15.
970 76. Zhu L, Phadtare S, Nariya H, Ouyang M, Husson RN, Inouye M. The
971 mRNA interferases, MazF-mt3 and MazF-mt7 from *Mycobacterium tuberculosis*
972 target unique pentad sequences in single-stranded RNA. Mol Microbiol.
973 2008;69(3):559-69.
974 77. Zhu L, Zhang Y, Teh JS, Zhang J, Connell N, Rubin H, et al.
975 Characterization of mRNA interferases from *Mycobacterium tuberculosis*. J Biol
976 Chem. 2006;281(27):18638-43.
977 78. Vandal OH, Pierini LM, Schnappinger D, Nathan CF, Ehrt S. A membrane
978 protein preserves intrabacterial pH in intraphagosomal *Mycobacterium*
979 *tuberculosis*. Nature medicine. 2008;14(8):849-54.
980 79. Lofthouse EK, Wheeler PR, Beste DJ, Khatri BL, Wu H, Mendum TA, et
981 al. Systems-based approaches to probing metabolic variation within the
982 *Mycobacterium tuberculosis* complex. PLoS One. 2013;8(9):e75913.
983 80. Schaefer WB, Lewis CW, Jr. Effect of oleic acid on growth and cell
984 structure of mycobacteria. J Bacteriol. 1965;90(5):1438-47.
985 81. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, Sassetti
986 CM. High-resolution phenotypic profiling defines genes essential for
987 mycobacterial growth and cholesterol catabolism. PLoS Pathog.
988 2011;7(9):e1002251.
989 82. Hamoen LW. Cell division blockage: but this time by a surprisingly
990 conserved protein. Mol Microbiol. 2011;81(1):1-3.
991 83. Tchigvintsev A, Tchigvintsev D, Flick R, Popovic A, Dong A, Xu X, et al.
992 Biochemical and Structural Studies of Conserved Maf Proteins Revealed
993 Nucleotide Pyrophosphatases with a Preference for Modified Nucleotides.
994 Chemistry & Biology. 2013;20(11):1386-98.
995 84. Gago G, Kurth D, Diacovich L, Tsai SC, Gramajo H. Biochemical and
996 structural characterization of an essential acyl coenzyme A carboxylase from
997 *Mycobacterium tuberculosis*. J Bacteriol. 2006;188(2):477-86.
998 85. Desnoyers G, Morissette A, Prevost K, Masse E. Small RNA-induced
999 differential degradation of the polycistronic mRNA *iscRSUA*. EMBO J.
1000 2009;28(11):1551-61.
1001 86. Florczyk MA, McCue LA, Stack RF, Hauer CR, McDonough KA.
1002 Identification and characterization of mycobacterial proteins differentially
1003 expressed under standing and shaking culture conditions, including Rv2623 from
1004 a novel class of putative ATP-binding proteins. Infect Immun. 2001;69(9):5777-
1005 85.
1006 87. Bardarov S, Bardarov Jr S, Jr., Pavelka Jr MS, Jr., Sambandamurthy V,
1007 Larsen M, Tufariello J, et al. Specialized transduction: an efficient method for
1008 generating marked and unmarked targeted gene disruptions in *Mycobacterium*
1009 *tuberculosis*, *M. bovis* BCG and *M. smegmatis*. Microbiology. 2002;148(Pt
1010 10):3007-17.

88. Beauregard A, Smith EA, Petrone BL, Singh N, Karch C, McDonough KA, et al. Identification and characterization of small RNAs in *Yersinia pestis*. *RNA Biol.* 2013;10(3):397-405.
89. Darty K, Denise A, Ponty Y. VARNA: Interactive drawing and editing of the RNA secondary structure. *Bioinformatics.* 2009;25(15):1974-5.
90. Huff J, Czyz A, Landick R, Niederweis M. Taking phage integration to the next level as a genetic tool for mycobacteria. *Gene.* 2010;468(1-2):8-19.
91. Ding Y, Chan CY, Lawrence CE. Sfold web server for statistical folding and rational design of nucleic acids. *Nucleic Acids Res.* 2004;32(Web Server issue):W135-41.
92. Zadeh JN, Steenberg CD, Bois JS, Wolfe BR, Pierce MB, Khan AR, et al. NUPACK: Analysis and design of nucleic acid systems. *J Comput Chem.* 2011;32(1):170-3.
93. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Research.* 2003;31(13):3406-15.
94. Sato K, Hamada M, Asai K, Mituyama T. CENTROIDFOLD: a web server for RNA secondary structure prediction. *Nucleic Acids Res.* 2009;37(Web Server issue):W277-80.
95. Vasudeva-Rao HM, McDonough KA. Expression of the *Mycobacterium tuberculosis* *acr*-coregulated genes from the DevR (DosR) regulon is controlled by multiple levels of regulation. *Infect Immun.* 2008;76(6):2478-89.
96. Purkayastha A, McCue LA, McDonough KA. Identification of a *Mycobacterium tuberculosis* Putative Classical Nitroreductase Gene Whose Expression Is Coregulated with That of the *acr* Gene within Macrophages, in Standing versus Shaking Cultures, and under Low Oxygen Conditions. *Infection and Immunity.* 2002;70(3):1518-29.

Figure Legends

Figure 1. Secondary Structure modeling of 3' sequences beyond the mapped 3' end of Mcr11. A. The DNA sequence of the *mcr11* gene and extended 3' sequence used for modeling experiments is shown. The *mcr11* gene is shown in capital letters, and nucleotides where 5' and 3' boundaries have been mapped by RACE are indicated by arrows and shown in capitalized, bolded black text. Flanking sequences are in italics, and the Rv1264 stop codon in bolded in red text. The last nucleotide on the 3' side of *mcr11* that was included in modeling experiments is in bold, lowercase black text. An asterisk indicates 3' ends reported by DiChiara et al and DeJesus et al. Positions of mapped nucleotides on the Mtb chromosome are shown above the text. B. Secondary structure diagrams of Mcr11 from 5' position 1413227 and extended 3' native sequences. The synthetic idealized intrinsic termination control (tt_{sbi}B) is also modeled onto Mcr11 from the longest 3' end reported at position 1413094; the last nucleotide of native sequence 3' to Mcr11 is indicated by a black arrow. Black nucleotides indicate bases in the mapped boundaries of the *mcr11* gene, red base pairs indicate base pairs beyond the mapped 3' end of Mcr11 at position 1413107, except all uracils (Us) are shown in blue. An asterisk indicates that last nucleotide modeled in (C.). C. The secondary structure models with the lowest minimum free energies (MFE) of a shorter untested native Mcr11 TSE with the most U rich sequence at the 3' end of the putative terminator. The MFE of each structure is shown below each diagram.

Figure 2. TSEs decrease transcriptional read-through of Mcr11-GFPv

reporters, but Mcr11 is not robustly expressed in Msm, even in the

presence of *abmR* from Mtb. A. A schematic representation of GFPv

fluorescence-based reporter assay to determine the functionality of TSEs, and a

synthetic idealized intrinsic termination control (tt_{sb1B}). B. GFPv fluorescence

assay used to measure promoter activity and read-through of TSEs of *mcr11* in

late stationary phase Msm, which lacks a native *mcr11* locus. The promoter *P_{tuf}*

served as a positive control. The various TSE constructs tested are indicated

underneath the corresponding bar. Statistical comparisons are relative to

P_{mcr11}. C. The % termination of constructs tested in (B.). Statistical

comparisons are relative to TSE1. D. Northern blot analysis of Mcr11 expression

(M) in Msm with various *mcr11* + TSE constructs. Ten ug of total Msm RNA was

loaded, whereas 3 ug of the BCG positive control was loaded. The HisT tRNA

(H) was used as a loading control. E. GFPv fluorescence assay used to measure

promoter activity in Msm. Statistical comparisons are relative to *P_{mcr11}* or

between 24h and 28h as indicated. Results are the means of 3 biological

replicates. Statistical analysis conducted with an unpaired, 2-tailed Student's t-

test. Asterisks indicate significance as follows: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$,

**** $p < 0.0001$.

Figure 3. Efficiency of TSEs are positively regulated in response to growth

phase in BCG and function significantly better in Mtb. A. GFPv fluorescence

assay used to measure promoter activity and read-through of the TSEs of *mcr11*

in mid-log phase BCG in hypoxic (1.3% O₂, 5% CO₂), shaking conditions. A promoterless (-) construct was used as a negative control and the promoters *Ptuf* and *Pgyr* served as positive controls. The various TSE constructs tested are indicated underneath the corresponding bar. Statistical comparisons were made to *Pmcr11*. B. As in (A), but assayed in late stationary phase. C. A comparison of % termination observed in mid-log phase (solid bars) and late stationary phase (hatched bars) BCG. Statistical comparisons were made between mid-log and stationary phase. D. GFPv fluorescence assay used to measure promoter activity and read-through of the TSEs of *mcr11* in mid-log phase Mtb in hypoxic (1.3% O₂, 5% CO₂), shaking conditions. A promoterless (-) construct was used as a negative control and the promoters *Ptuf* and *Pgyr* serve as positive controls. The various TSE constructs tested are indicated underneath the corresponding bar. Statistical comparisons are made to *Pmcr11*. E. As in (D), but assayed in late stationary phase. Statistical comparisons are made to *Pmcr11*. F. A comparison of % termination observed in late stationary phase Msm, BCG, and Mtb. Statistical comparisons are made to Mtb. Results are the means of 3 biological replicates. Statistical analysis conducted with an unpaired, 2-tailed Student's t-test. Asterisks indicate significance as follows: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Figure 4. Different Mcr11 TSEs do not alter the size of stable Mcr11. A. Northern blot analysis of Mcr11 expression in the indicated strains of BCG in hypoxic (1.3% O₂, 5% CO₂) late stationary phase. B. Northern blot analysis of

Mcr11 expression in the indicated strains of Mtb in hypoxic late stationary phase. The tRNA HisT is used as a loading control. Results representative of 2-3 independent repeats.

Figure 5. Termination at a sub-optimal TSE does not require a trans-gene for stabilization of Mcr11. A. A schematic of the transgene fusion constructs. *Mcr11* complementation was provided with (1) or without (2) the transgene GFPv fused to the end of *mcr11* downstream of sub-optimal terminator TSE1. An *Mcr11* complementation construct was also tested with TSE3 (3). B. Northern blot analysis of *Mcr11* expression in Mtb grown to late stationary phase in hypoxia (1.3% O₂, 5% CO₂). HisT was used as a loading control. C. Northern blot analysis *Mcr11* expression across growth phase in BCG, indicated below. HisT was used as a loading control. D. qPCR analysis of *Mcr11* expression in mid-log and late stationary phase BCG, normalized to *sigA* expression. Results are the representative of 2-3 biological replicates. Statistical analysis conducted with an unpaired, 2-tailed Student's t-test. Asterisks indicate significance as follows: ** p<0.01, *** p<0.001.

Figure 6. $\Delta mcr11$ has a disrupted *abmR* promoter, resulting in reduced expression of AbmR protein in BCG and Mtb. A. The *mcr11* locus with the position of the hygromycin knockout cassette is shown. The regions of DNA used to create *promoter::lacZ* fusions are shown. Fragment (1.) includes the *Rv1264-abmR* intergenic region, which includes the *mcr11* locus. Fragment (2.) includes

the *mcr11-Rv1265* sequence that is available in the $\Delta mcr11$ strain. B. Quantification of western blot analysis from BCG grown to late-log phase in ambient, shaking conditions. C. Quantification of western blot analysis from Mtb grown to late-log phase in hypoxic (1.3% O₂, 5% CO₂), shaking conditions. AbmR was detected with poly-clonal anti-sera, and levels were normalized to GlcB levels, as detected by a monoclonal antibody. D. β -Galactosidase activity assays using the promoter:*lacZ* fusions shown in (A.) in Wt BCG (gray bars) and MTB (black bars) grown to late-log phase in ambient, shaking conditions. An asterisk * indicates p-value < 0.05 using an unpaired Student's t-test. Results representative of 2-3 biological repeats.

Figure 7. Bioinformatic modeling of Mcr11 targets reveals potential regulatory targets that are involved in central metabolism and cell division.

A. The organization of the *dlaT-lipB* locus, with the position and potential base-pairing interactions between the mRNA and Mcr11 shown below. The transcriptional start site of the operon is shown with a thin black arrow. B. As in (A.), but for the *accD5-Rv3282* locus. Dashes indicate Watson-Crick base pairs, dots indicate non-Watson-Crick base pairs, and a blank space indicates no interaction between bases. C. The sequence of the Mcr11 RNA with mapped 5' and 3' ends shown in bolded letters. The portion of the sRNA predicted to interact with targets shown in (A) and (B) is underlined in black. D. The MFE secondary structure of Mcr11 as predicted by RNAstructure, with the portion of the sRNA predicted to interact with targets shown in (A) and (B) outlined in black.

Figure 8. $\Delta mcr11$ strains of BCG and Mtb are defective for growth in fatty-acid depleted media and predicted regulatory targets of Mcr11 are dysregulated at the mRNA level. A. Mtb was grown for 12 days in under hypoxic (1.3% O₂, 5% CO₂), shaking conditions in -OA media (7H9 + 0.2% glycerol, 10% ADC, and 0.05% Tyloxapol). Gene expression was measured by qRT-PCR and normalized to the reference gene *sigA*. Comparison made of each strain versus $\Delta mcr11$. Complementation strains included a single-copy of *mcr11* with TSE3 fused to *GFPv* or a single-copy of the *abmR* locus and *mcr11* with TSE4. B. Mtb was grown for 7 days in under hypoxic, shaking conditions in +OA media (7H9 + 0.2% glycerol, 10% OADC, and 0.05% Tyloxapol). Gene expression was measured by qRT-PCR and normalized to the reference gene *sigA*. C. BCG was grown for 12 days in under hypoxic, shaking conditions in -OA media. Gene expression was measured by qRT-PCR and normalized to the reference gene *sigA*. D. BCG was grown for 12 days in under hypoxic, shaking conditions in +OA media. Gene expression was measured by qRT-PCR and normalized to the reference gene *sigA*. E. Growth curve of Mtb grown in hypoxic, shaking conditions in -OA media. Growth was surveyed by measuring the optical density at 620 nm (OD₆₂₀). F. Growth curve of Mtb grown in hypoxic, shaking conditions in +OA media. Growth was surveyed by measuring OD₆₂₀. G. As in (E.), but with BCG. H. As in (F.), but with BCG. Results are the means of 3 biological replicates. Statistical comparisons made of each strain versus $\Delta mcr11$ using an unpaired, 2-tailed Student's t-test. Asterisks indicate significance as follows: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Figure 9. Model of Mcr11 function in Mtb.

Expression of *mcr11* is activated by cAMP, chronic infection in the lungs of mice, and by advancing growth phase and the ATP-binding transcription factor AbmR. Native 3' sequence elements (TSEs, predicted secondary structure shown in red) promote the transcriptional termination and stability of *Mcr11*. The predicted secondary structure of mature *Mcr11* is shown in black. *Mcr11* regulates the expression of genes involved in the central metabolism and growth of *Mtb*, possibly through a base-pairing interaction between *Mcr11* and target mRNAs. *Mcr11* is required for the optimal growth of *Mtb* in the absence of fatty acids

Supporting information

S1 Figure. Generation and confirmation of *mcr11* knock-out and

complementation strains. A. A diagram of the *mcr11* locus and the relative

position of the hygromycin resistance cassette. Lines with arrows indicated the

DNA sequence included in the various listed complementation strains. B. PCR

confirmation of *mcr11* knockout and complementation strains of BCG. C. PCR

confirmation of *mcr11* knockout and complementation strains of Mtb. D. Northern

blot analysis of the indicated strains of BCG from 3 µg of total RNA harvested

from late stationary phase cultures grown in hypoxic (1.3% O₂, 5% CO₂), shaking

conditions. E. Northern blot analysis of the indicated strains of Mtb from 5 µg of

total RNA harvested from late-log phase cultures grown in hypoxic (1.3% O₂, 5%

CO₂), shaking conditions. The number above the lane indicates the identity of

each sample. The column to the left of the rows indicates which gene was

amplified or which RNA was probed by Northern blot.

S2 Figure. FACS analysis of TSEs in Msm. FACS analysis of GFPv

fluorescence of 20,000 events for each sample as indicated by the label to the

left of the histogram. Representative of three independent repeats.

S3 Figure. *abmR* contributes to the termination of Mcr11 transcripts. A.

GFPv fluorescence assay used to measure *mcr11* promoter activity in mid-log

phase Mtb in hypoxic (1.3% O₂, 5% CO₂), shaking conditions. B. The %

termination in mid-log phase. The various TSE constructs tested are indicated

underneath the corresponding bar. C. Promoter reporter assay as in (A), but in

late stationary phase. D. The % termination, as in (B), but in late stationary

phase. Results representative of 3 biological replicates. Statistical analysis conducted with an unpaired, 2-tailed Student's t-test. Comparison made versus *MtbΔabmR* in A. and C., and versus Wt in B. and D. Asterisks indicate significance as follows: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

S4 Figure. Secondary structure of Mcr11 RNA generated by multiple modeling algorithms. A. The CentroidFold secondary structure using the CONTRAfold inference engine. B. The -54.40 kcal/mol MFE structure generated using Mfold. C. The -45.40 kcal/mol MFE strcture generated using NUPACK. D. The RNAfold centroid structure. E. The -54.00 kcal/mol MFE structure generated using RNAfold. F. The -53.80 kcal/mol MFE structure generated using RNAstructure. G. The ensemble centroid structure generated using Sfold. H. The -54.40 kcal/mol MFE structure generated using Sfold.

S5 Figure. Protein levels of predicted regulatory targets of Mcr11 are not dysregulated in *MtbΔmcr11* during hypoxia in the absence of added fatty acids. A. *Mtb* was grown for 12 days in under hypoxic, shaking conditions in -OA media. Gene expression was measured by qRT-PCR and normalized to the reference gene *sigA*. Comparison made of each strain versus *MtbΔmcr11*. B. *Mtb* was grown for 12 days in under hypoxic (1.3% O₂, 5% CO₂), shaking conditions in Middlebrook 7H9 + 0.2% glycerol, 10% ADC, and 0.05% Tyloxapol (-OA) media. Protein levels were assayed by Western blot analysis with polyclonal α-Lipoate, polyclonal α-PknA, and monoclonal α-GlcB antibodies. GlcB serves as a loading and transfer control. Representative of three biological repeats.

S6 Figure. Regulation of predicted targets of Mcr11 is condition specific in

BCG and Mtb. A. BCG grown for 12 days in under hypoxic (1.3% O₂, 5% CO₂),

shaking conditions in Middlebrook 7H9 + 0.2% glycerol, 10% OADC, and 0.05%

Tyloxapol (+OA). Gene expression was measured by qRT-PCR and normalized

to the reference gene *sigA*. G.-H. Mtb was grown for 7 days in under hypoxic

(1.3% O₂, 5% CO₂), shaking conditions in Middlebrook 7H9 + 0.2% glycerol, 10%

OADC, and 0.05% Tween (+OA) and treated with vehicle control (Control) or 10

mM dibutyryl cAMP on day 3 (+db cAMP). Gene expression was measured by

qRT-PCR and normalized to the reference gene *sigA*. Representative of 2-3

biological repeats. Statistical analysis conducted with an unpaired, 2-tailed

Student's t-test. Comparison made of each strain versus *Δmcr11*. Asterisks

indicate significance as follows: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

S1 Table. Plasmids used in the study.

S2 Table. Primers used in the study.

S3 Table. Stress does not impact the efficiency of TSEs in BCG or Mtb.

S4 Table. Results of TargetRNA and TargetRNA2 predictions of Mcr11

regulatory targets.

A.

1413227
 5' *tttttggt* **ATCG** *AAGCAGGCCCGGTTAGTGACCAATCGAAAGTGCCGGAAGACGGGGTGAAGGCCGGCCGCGCAAGACCCGCAGAAGGGCGGTGTCAG*
 1413107 1413094
 * *
ACGCCCCCGAGAGTCACGCCGGGTCTGCCCA *tgtgtaccggtgtgcctgcta* *cggtgacgagccggccaaatcgtcgtcttgggccgcgccgccgg*
agccggtgcgagtgggcccctcgccggactcgaaaaagcctgacgtcaccccggattc 3'




Figure 1




Figure 2




Figure 3




Figure 5





Figure 6

A.


bioRxiv preprint doi: <https://doi.org/10.1101/616912>; this version posted April 23, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Predicted Mcr11 Interaction Sequence



B.

Predicted Mcr11 Interaction Sequence



C. 5' **ATCGAAGCAGGCCCGGTTAGTGACCAATCGAAAGTGCCGGAAGA**
CGGGGTGAAGGCCGGCCGCGCAAGACCCGCAGAAGGCGGTGTCAGA
 CGCCCCCGAGAGTCACGCCGGGTCTGCCCA 3'




Figure 7





Figure 8

Figure 8




Figure 9





Figure 4